SKL 10406

Drug Profile

SKL 10406

Alternative Names: SKL DEP; SKL-10406

Latest Information Update: 11 Apr 2016

Price : $50

At a glance

  • Originator SK Holdings
  • Developer SK biopharmaceuticals
  • Class Antidepressants
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 03 Jul 2007 SK Bio-Pharmaceuticals is now called SK Drug Development Center
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top